Clinical Trial

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Study acronym: PROPEL
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
Protocol Amendment History 6 changes
notable Trial sites expanded: 28 -> 31 locations 2026-07-24
notable Trial sites expanded: 17 -> 28 locations 2026-07-01
notable Trial sites expanded: 10 -> 17 locations 2026-05-30
notable Trial sites expanded: 4 -> 10 locations 2026-05-05
critical Recruitment opened 2026-04-04
notable Trial sites expanded: 0 -> 4 locations 2026-04-04
Trial Details
NCT Number NCT07473778
Lead Sponsor Gilead Sciences
Conditions HIV Infections
Enrollment 3,000 participants
Start Date 2026-03-17
Primary Completion 2028-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-23